Clementia Pharmaceuticals
Montréal
About Clementia Pharmaceuticals
Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 5,001 – 10,000
- Estimated revenue: $10K – $50K
- Total funding: $230.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Aug 2017)
- Ticker: nasdaq:CMTA
- Website: clementiapharma.com
- Phone: (514) 940-3600
Industries & Categories
Biopharma, Biotechnology, Medical
Canonical: https://fsome.com/organization/clementia-pharmaceuticals-168704 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.